Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma

PURPOSE: Atezolizumab + bevacizumab is the new standard of care for systemic treatment-naïve, unresectable hepatocellular carcinoma (HCC). This exploratory study investigated on-treatment alpha-fetoprotein (AFP) response as a potential surrogate biomarker of prognosis for the combination therapy. EX...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Andrew X., Dayyani, Farshid, Yen, Chia-Jui, Ren, Zhenggang, Bai, Yuxian, Meng, Zhiqiang, Pan, Hongming, Dillon, Paul, Mhatre, Shivani K., Gaillard, Vincent E., Hernandez, Sairy, Kelley, Robin Kate, Sangro, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662926/
https://www.ncbi.nlm.nih.gov/pubmed/35435967
http://dx.doi.org/10.1158/1078-0432.CCR-21-3275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662926/
https://www.ncbi.nlm.nih.gov/pubmed/35435967
http://dx.doi.org/10.1158/1078-0432.CCR-21-3275

Ejemplares similares